Antibodies against Epstein-Barr-Virus (EBV)
PLEASE INQUIRE REGARDING FDA STATUS - 1.800.913.2022
Indirect Immunofluorescence Test: BIOCHIP Sequence EBV (copy 1)
- Gold standard for the determination of antibodies against the EBV-CA antigens (Epstein-Barr virus capsid antigen), EBV-EA (Epstein-Barr early antigen) and EBNA (Epstein-Barr nuclear antigen).
- Indication: infectious mononucleosis, Burkitt's lymphoma, nasopharyngeal carcinoma (NPC).
- IgG antibodies against EBV-CA indicate an EBV infection. An at least twofold increase in titer and the absence of antibodies against EBNA at the same time is characteristic for the early phase of the infection. IgM antibodies against EBV-CA and antibodies against EBV-EA can also be found in acute infections, but they do not necessarily always occur. The presence of antibodies against EBNA generally indicates the late phase of an EBNA infection.
- In cases of an acute EBV infection which cannot be reliably discriminated from a relapse or reinfection, the determination of the antibody avidity using a modified immunofluorescence test as an additional parameter is useful. This requires an additional incubation with urea solution (ZF 1130-0801). The determination of low-avidity antibodies against EBV-CA indicates an acute infection.
- For the monospecific confirmation of EBV-CA antibodies in the same test procedure the BIOCHIP containing ECV-CA is supplemented with the antigen substrates gp125 antigen (native) and p19 antigen (recombinant) (EUROPLUS FI 2791-####-20 G or M).
- For highly differentiated diagnostics the BIOCHIP Sequence EBV (FI 2799-####-1 X) can be supplemented by using the antigens gp125 and p19 (EUROPLUS FI 2799-####-21 X). Further anti-EBV test kits for indirect immunofluorescence:
- Due to the high prevalence of anti-EBV-CA IgA in NPC patients, the parameter is well suited for screening. Confirmation of the result by determination of IgA antibodies against EBV-EA is recommended. Further anti-EBV test kits for indirect immunofluorescence:
| Substrate | Order No. |
| Substrate | Order No. |
EBV-CA | FI 2791-#### G or M | EBV-EA | FI 2795-#### A or G | ||
EBNA | FI 2793-#### G | EBV-CA & EBV-EA | FI 2791-####-2 A or G |
Microplate ELISA: Anti-EBV-CA, Anti-EBNA-1, Anti-EBV-EA
- Incubated ELISA Anti-EBNA-1.
- Specific confirmatory test for antibodies against EBV-CA, EBNA-1 or EBV-EA.
- Indications: infectious mononucleosis, Burkitt-lymphoma, nasopharyngeal carcinoma.
- Serum dilution 1 : 100; conjugate class anti-IgA, -IgG or IgM, POD-labelled.
- 1-point calibration, semi-quantitative (IgA, IgM) or 3-point calibration, quantitative (IgG). Identical incubation conditions and times: all tests can be combined without difficulty on one and the same microplate.
- EBV-CA: native antigen, purified by affinity chromatography; EBNA-1 and EBV-EA: recombinant antigen.
- IgM test kit includes IgG/RF absorbent in sample buffer for IgG absorption in preparation for the determination of specific IgM class antibodies.
- Available individual ELISA:
Antigen |
| Order No. |
EBV-CA | EI 2791-9601 A, G or M | |
EBNA-1 | EI 2793-9601 G | |
EBV-EA | EI 2795-9601 A, G or M |
Determination of Low-Avidity Antibodies against EBV-CA
- Avidity of antibodies against EBV-CA (IgG).
- An alternative principle for the serological diagnosis of fresh infections with EBV has been established by investigating the antibody avidity.
- The first reaction of the immune system following an infection is the formation of low-avidity antibodies. As the infection proceeds, increasingly antigen-adapted IgG is formed, and avidity grows. As long as high-avidity IgG is not yet detected in the serum, it can be assumed that the infection is still in an early stage.
- To identify low-avidity antibodies against EBV-CA in a patient´s serum, two microplate ELISA or immunofluorescence tests are performed in parallel: one test is carried out in the conventional way, the other one includes urea treatment between incubations with patient´s serum and peroxidase-labelled anti-human IgG, resulting in the detachment of low-avidity antibodies from the antigens.
- Low-avidity antibodies against EBV-CA are present if the ELISA extinction is significantly reduced by urea treatment. For an objective interpretation, the relative avidity index (RAI) can be calculated out of the measured values with and without urea incubation.
- With the immunofluorescence test the presence of low-avidity antibodies has been proved if the test using urea treatment gives a far weaker fluorescence than the two-step test.
EUROLINE: EBV Profile 2
- Differentiation of antibodies against Epstein-Barr virus antigens.
- Indications: infectious mononucleosis, Burkitt-lymphoma, nasopharyngeal carcinoma.
- Serum dilution 1 : 100; conjugate class anti-human IgG or IgM, AP-labelled.
- With the EUROLINE EBV Profile 2, five different antibodies can be determined: antibodies against, VCA p19, EBNA-1, p22, EA-D.
- Recombinant antigens (exception: VCA gp125, native, purified by affinity chromatography).
- EBNA-1 (IgG) negative und VCA (IgG and IgM) positive: acute (fresh) infection.
- EBNA-1 (IgG) and VCA (IgG) positive and VCA (IgM) negative: late phase of infection.
- EBNA-1 (IgG) negative, but band p22 (IgG) and VCA (IgG) positive: late phase of infection with loss of anti-EBNA-1.
- Test strips can be automatically incubated and evaluated using the systems EUROBlotMaster und EUROLineScan.
Westernblot: Anti-EBV
- Incubated Westernblot Anti-EBV.
- Specific confirmatory test for the detection of antibodies against Epstein-Barr virus antigens, differentiation of antibodies against Epstein-Barr virus antigens.
- Indications: infectious mononucleosis, Burkitt-lymphoma, nasopharyngeal carcinoma.
- Serum dilution 1 : 50; conjugate class anti-IgG or anti-IgM, AP-labelled.
- Antigens: whole antigen, SDS extract.
- Bands from all specific antigens are included and clearly separated.
- EBNA-1 (IgG) negative und VCA (IgG and IgM) positive: acute (fresh) infection.
- EBNA-1 (IgG) and VCA (IgG) positive and VCA (IgM) negative: late phase of infection.
- EBNA-1 (IgG) negative, but band p22 (IgG) and VCA (IgG) positive: late phase of infection with loss of anti-EBNA-1.
- Test strips can be automatically incubated and evaluated using the systems EUROBlotMaster und EUROLineScan.
